1. Home
  2. GNPX vs CHGA Comparison

GNPX vs CHGA Comparison

Compare GNPX & CHGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genprex Inc.

GNPX

Genprex Inc.

HOLD

Current Price

$3.95

Market Cap

3.2M

Sector

Health Care

ML Signal

HOLD

Logo Change Agents Corporation Common Stock

CHGA

Change Agents Corporation Common Stock

N/A

Current Price

$0.17

Market Cap

3.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GNPX
CHGA
Founded
2009
N/A
Country
United States
United States
Employees
13
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2M
3.0M
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
GNPX
CHGA
Price
$3.95
$0.17
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
131.5K
270.3K
Earning Date
05-11-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.18
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$0.16
52 Week High
$12.97
$0.24

Technical Indicators

Market Signals
Indicator
GNPX
CHGA
Relative Strength Index (RSI) 45.44 30.02
Support Level $0.73 N/A
Resistance Level $5.24 $0.23
Average True Range (ATR) 0.56 0.02
MACD -0.26 -0.00
Stochastic Oscillator 10.66 24.98

Price Performance

Historical Comparison
GNPX
CHGA

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

About CHGA Change Agents Corporation Common Stock

Change Agents Corp is an artificial intelligence software company focused on developing agentic AI applications designed to help small businesses, brands, and content creators increase revenue, improve digital discoverability, and automate content creation. The company's current portfolio includes Beacon, an AI Search Optimization platform, and Catch-Up, an autonomous AI-powered content creation platform. Through its scalable Software-as-a-Service (SaaS) business model, it is focused on delivering AI solutions that create measurable customer value while generating recurring subscription revenue and long-term shareholder returns.

Share on Social Networks: